MannKind Corporation announced that a grant from Breakthrough T1D (formerly JDRF) will be used to support the Phase 2 INHALE-1ST trial of Afrezza in children aged 10 and up with a recent Type 1 diabetes diagnosis, which was initiated earlier this year. The company says that it has completed enrollment in the pilot phase of the study. The FDA recently approved use of Afrezza in children aged 6 and over.
MannKind CEO Michael Castagna commented, “This collaboration with Breakthrough T1D represents meaningful external support of both Afrezza’s potential role in transforming insulin therapy and of the INHALE-1ST trial. We believe this reflects growing confidence and increased interest in advancing the potential of inhaled insulin in newly-diagnosed pediatric patients.”
Breakthrough T1D Director of Research Jonathan Rosen said, “Advancing therapies that can reduce the daily burden of living with type 1 diabetes is a Breakthrough T1D priority. Afrezza has made a difference in the lives of adults with T1D, and now we can assess its impact in the new-onset pediatric population. If Afrezza can help children and adolescents start off their T1D journeys with a well-tolerated treatment and good time-in-range, that’s a win for our community.
Read the MannKind Corporation press release
